Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Ashutosh Kumar Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Chalcones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Amrita Vishwa Vidyapeetham University.
Abstract (Originalsprache)
Eight derivatives of benzyloxy‐derived halogenated chalcones ( BB1‐BB8 ) were synthesized and tested for their ability to inhibit monoamine oxidases (MAOs). MAO‐A was less efficiently inhibited by all compounds than MAO‐B. Additionally, the majority of the compounds displayed significant MAO‐B inhibitory activities at 1 μM with residual activities of less than 50%. With an IC 50 value of 0.062 μM, compound BB4 was the most effective in inhibiting MAO‐B, followed by compound BB2 (IC 50 = 0.093 μM). The lead molecules showed good activity than the reference MAO‐B inhibitors (Lazabemide IC 50 = 0.11 μM and Pargyline Pargyline IC 50 = 0.14). The high selectivity index (SI) values for MAO‐B were observed in compounds BB2 and BB4 (430.108 and 645.161, respectively). Kinetics and reversibility experiments revealed that BB2 and BB4 were reversible competitive MAO‐B inhibitors with K i values of 0.030 ± 0.014 and 0.011 ± 0.005 μM, respectively. Swiss target prediction confirmed the high probability in the targets of MAO‐B for both compounds. Hypothetical binding mode revealed that the BB2 or BB4 is similarly oriented to the binding cavity of MAO‐B. Based on the modelling results, BB4 showed a stable confirmation during the dynamic simulation. From these results, it was concluded that BB2 and BB4 were potent selective reversible MAO‐B inhibitors and they can be considered drug candidates for treating related neurodegenerative diseases such as Parkinson's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India.
- Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon, Korea.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
- Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah, Saudi Arabia.
- Department of Chemistry, Sri Venketeswara College, University of Delhi, New Delhi, India.
ORCID-Profile: Orazio Nicolotti
Förderung
- Amrita Vishwa Vidyapeetham University
Zitieren
APA
Singh, A. K., Kim, S. M., Oh, J. M., Abdelgawad, M. A., Ghoneim, M. M., Rangarajan, T. M., Kumar, S., Sudevan, S. T., Trisciuzzi, D., Nicolotti, O., Kim, H., & Mathew, B. (2023). Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14238
Vancouver
Singh AK, Kim SM, Oh JM, Abdelgawad MA, Ghoneim MM, Rangarajan TM, et al. Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14238
BibTeX
@article{Singh2023,
author = {Singh, Ashutosh Kumar and Kim, Seong-Min and Oh, Jong Min and Abdelgawad, Mohamed A and Ghoneim, Mohammed M and Rangarajan, T M and Kumar, Sunil and Sudevan, Sachithra Thazhathuveedu and Trisciuzzi, Daniela and Nicolotti, Orazio and Kim, Hoon and Mathew, Bijo},
title = {Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14238}
}
EUVIMED